Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Status unconfirmed · Phase 2

Conditions studied: Pain, Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have prostate cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00005960

Run by

Amgen

Starts

1999-10-01

Last updated by the study team

2013-12-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Wilshire Oncology Medical Group, Inc. — Los Angeles, California, United States
• Geffen Cancer Center and Research Institute — Vero Beach, Florida, United States
• Arena Oncology Associates — Great Neck, New York, United States
• New York Medical College — Valhalla, New York, United States
• N.W. Carolina Oncology & Hematology, P.A. — Hickory, North Carolina, United States
• Associates of Hematology/Oncology — Upland, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.